Top 10 Companies in the (S)-1-(2-Methoxyphenyl)-ethylamine (CAS 68285-24-5) Market (2026): Leaders Shaping the Specialty Chiral Amine Landscape

MARKET INSIGHTS

Global (S)-1-(2-Methoxyphenyl)-ethylamine (CAS 68285-24-5) market size reached USD 28.4 million in 2025 and is projected to grow to USD 52.7 million by 2034, translating to an annual growth rate of 7.3 % over the forecast horizon.

(S)-1-(2-Methoxyphenyl)-ethylamine is a chiral primary amine distinguished by a methoxy group positioned ortho to the phenyl ring. As an enantiomerically pure building block, it serves a pivotal function in asymmetric synthesis and is extensively applied in pharmaceutical and fine‑chemical sectors for crafting optically active compounds, chiral auxiliaries, and resolving agents.

The market is underpinned by a rising appetite for enantioselective synthesis in drug development, expanding use in active pharmaceutical ingredient (API) production, and a growing preference for chiral intermediates across specialty chemical manufacturing. Regulatory emphasis on stereospecific therapeutics and stringent requirements for enantiomeric purity in pharmaceutical formulations further sustain demand. Key suppliers include Sigma‑Aldrich (Merck KGaA), TCI Chemicals, and Alfa Aesar, among others offering high‑optical‑purity grades.

(S)-1-(2-Methoxyphenyl)-ethylamine (CAS 68285-24-5) Market – View in Detailed Research Report

PRODUCT DEFINITION

The compound is a chiral amine with a single stereocenter, enabling it to be incorporated early in synthetic routes to generate enantiomerically pure molecules. Its methoxy substituent enhances electron density, facilitating reactions such as reductive amination, amide coupling, and imine formation. These attributes make it a versatile reagent for medicinal chemists and process developers seeking to introduce chirality efficiently.

Top 10 Companies in the Market

10. Carbolution Chemicals GmbH

Headquarters: Germany
Key Offering: High‑purity chiral intermediates for API synthesis

Carbolution leverages a robust German manufacturing base to deliver GMP‑compliant chiral amines. Its focus on stringent analytical validation ensures consistent enantiomeric excess, meeting the exacting standards of pharmaceutical clients.

Sustainability & Growth Initiatives:

• Investment in renewable energy for production facilities.
• Development of closed‑loop solvent recovery systems.
• Partnerships with academic institutions to advance asymmetric catalysis.

9. AstaTech Inc.

Headquarters: United States / China
Key Offering: Custom synthesis and bulk supply of enantiomerically pure amines

AstaTech combines North American distribution strength with Chinese manufacturing capacity, enabling rapid scaling for both research and commercial clients. Its flexible contract‑manufacturing model supports early‑stage drug discovery programs.

Sustainability & Growth Initiatives:

• Implementation of digital traceability for batch tracking.
• Adoption of green solvents in synthesis routes.
• Expansion of API‑grade product lines.

8. Combi‑Blocks Inc.

Headquarters: United States
Key Offering: Library of chiral building blocks and custom synthesis services

Combi‑Blocks supplies a curated catalog of chiral amines, including (S)-1-(2‑Methoxyphenyl)-ethylamine, to support both academic research and industry development. Its in‑house analytical team provides rapid purity assessment.

Sustainability & Growth Initiatives:

• Investment in flow‑chemistry platforms for scalable synthesis.
• Development of eco‑friendly purification methods.
• Collaboration with CROs for early‑stage project support.

7. Toronto Research Chemicals (TRC)

Headquarters: Canada
Key Offering: High‑purity research‑grade chiral amines

TRC’s Canadian operations focus on delivering laboratory‑grade chiral reagents with comprehensive analytical documentation. The company maintains strong ties with North American universities and research institutes.

Sustainability & Growth Initiatives:

• Use of biodegradable packaging materials.
• Optimization of synthesis routes to reduce hazardous waste.
• Engagement in joint research projects on chiral ligand design.

6. Fluorochem Ltd.

Headquarters: United Kingdom
Key Offering: GMP‑grade chiral intermediates for pharmaceutical development

Fluorochem’s UK base supports rigorous quality control, ensuring that chiral amines meet the stringent requirements of the European regulatory environment. Its portfolio includes both standard and custom‑synthesized compounds.

Sustainability & Growth Initiatives:

• Implementation of energy‑efficient manufacturing processes.
• Partnerships with EU research consortia to explore new asymmetric catalysts.
• Development of low‑toxicity solvent systems.

5. Haihang Industry Co., Ltd.

Headquarters: China
Key Offering: Bulk supply of enantiopure chiral amines for API production

Haihang combines China’s manufacturing scale with advanced chiral synthesis techniques, offering competitive pricing for bulk orders while maintaining high purity levels suitable for pharmaceutical use.

Sustainability & Growth Initiatives:

• Adoption of green chemistry principles in production lines.
• Investment in staff training for chiral process development.
• Expansion of product portfolio to include specialty chiral auxiliaries.

4. Sunway Pharm

Headquarters: China
Key Offering: Integrated chiral synthesis and resolution services

Sunway Pharm provides end‑to‑end solutions, from asymmetric synthesis to classical resolution, allowing clients to choose the most efficient route for their specific application.

Sustainability & Growth Initiatives:

• Implementation of continuous‑flow synthesis for higher throughput.
• Development of recyclable catalysts for chiral reactions.
• Collaboration with Chinese universities on asymmetric methodology research.

3. Alfa Aesar

Headquarters: United States
Key Offering: Catalog of high‑purity chiral amines and custom synthesis

Alfa Aesar’s extensive catalog includes (S)-1-(2‑Methoxyphenyl)-ethylamine, providing a reliable source for both research laboratories and industrial manufacturers. The company offers detailed certificates of analysis and strict batch documentation.

Sustainability & Growth Initiatives:

• Use of renewable feedstocks in synthesis processes.
• Implementation of waste‑minimization protocols.
• Expansion of API‑grade product lines.

2. TCI Chemicals

Headquarters: Japan
Key Offering: High‑purity chiral intermediates and custom synthesis services

TCI Chemicals supplies a wide range of chiral amines with rigorous analytical support, catering to both academic and pharmaceutical clients. Its emphasis on process scalability makes it a preferred partner for large‑scale API production.

Sustainability & Growth Initiatives:

• Development of green solvent alternatives for chiral synthesis.
• Investment in automated synthesis platforms.
• Partnerships with Japanese research institutes on novel chiral catalysts.

1. Sigma‑Aldrich (Merck KGaA)

Headquarters: Germany
Key Offering: Comprehensive catalog of chiral reagents and GMP‑compliant intermediates

Sigma‑Aldrich remains a benchmark supplier, providing a broad spectrum of chiral amines, including (S)-1-(2‑Methoxyphenyl)-ethylamine, with detailed purity data and regulatory documentation. Its global distribution network ensures timely delivery across all major markets.

Sustainability & Growth Initiatives:

• Implementation of energy‑efficient manufacturing practices.
• Development of low‑toxicity synthetic routes.
• Active participation in international chiral chemistry consortiums.

(S)-1-(2-Methoxyphenyl)-ethylamine (CAS 68285-24-5) Market – View in Detailed Research Report

(S)-1-(2-Methoxyphenyl)-ethylamine (CAS 68285-24-5) Market – View in Detailed Research Report

OUTLOOK

The next decade will see the specialty chiral amine market consolidate around a few key suppliers that combine advanced synthetic capabilities with robust quality management systems. Companies that invest in continuous‑flow technology, green chemistry, and digital traceability will capture a larger share of the API‑grade segment, where demand is driven by the need for single‑enantiomer drug candidates. In parallel, the agrochemical sector will slowly adopt chiral intermediates as regulatory frameworks increasingly favor stereoselective pesticides, opening modest growth avenues for chiral amine suppliers.

FUTURE TRENDS

• Expansion of flow‑chemistry platforms to reduce batch‑to‑batch variability.
• Greater emphasis on enzymatic and biocatalytic routes to achieve high enantiomeric excess with lower environmental impact.
• Integration of AI‑driven reaction optimization to accelerate discovery of new chiral catalysts.
• Growth of specialty markets in materials science, where chiral amines serve as ligands for metal‑organic frameworks and advanced polymers.
• Increased collaboration between academic institutions and industry to develop next‑generation chiral building blocks.